Demetrios Simos1, Golmehr Sajjady2, Melissa Sergi3, Mun Sem Liew4, Raffaele Califano5, Cheryl Ho6, Natasha Leighl7, Shane White4, Yvonne Summers5, William Petrcich8, Paul Wheatley-Price9. 1. Division of Medical Oncology, The Ottawa Hospital Cancer Centre, University of Ottawa and The Ottawa Hospital Research Institute, Ottawa, Ontario, Canada. 2. Division of General Internal Medicine, University of British Columbia, Vancouver, British Columbia, Canada. 3. Department of Internal Medicine, University of Toronto, Toronto, Ontario, Canada. 4. Joint Austin-Ludwig Oncology Unit, Olivia Newton-John Cancer and Wellness Centre, Austin Health, Melbourne, Australia. 5. Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom. 6. Division of Medical Oncology, The British Columbia Cancer Agency and University of British Columbia, Vancouver, British Columbia, Canada. 7. Division of Medical Oncology, Princess Margaret Hospital Cancer Centre/University Health Network and University of Toronto, Toronto, Ontario, Canada. 8. The Ottawa Hospital Research Institute, Clinical Epidemiology Program, Methods Centre, Ottawa, Ontario, Canada. 9. Division of Medical Oncology, The Ottawa Hospital Cancer Centre, University of Ottawa and The Ottawa Hospital Research Institute, Ottawa, Ontario, Canada. Electronic address: pwheatleyprice@toh.on.ca.
Abstract
INTRODUCTION: Small-cell lung cancer is an aggressive disease for which the mainstay of treatment is chemotherapy. Despite good initial responses most patients will relapse. Some will receive second-line therapy with clinical benefit, but for third-line chemotherapy there is little evidence to guide treatment decisions and the benefits of treatment are unknown. This study investigated the treatment of SCLC in the third-line setting. PATIENTS AND METHODS: An international, multicenter retrospective analysis of patients who received at least 3 lines of chemotherapy for their SCLC was performed. RESULTS: From 2000 to 2010, 120 patients were identified from 5 centers: median age 61, 40% (n = 72) limited stage, and 79% (n = 95) Eastern Cooperative Oncology Group performance status of 0 to 1. Only 22% of these patients received 3 distinct lines of chemotherapy. The remainder were rechallenged with a chemotherapy regimen used at least once previously. Six percent received platinum-based chemotherapy in all 3 lines. In third-line, response rate was 18% and median overall survival was 4.7 months. Factors associated with longer survival included normal baseline LDH levels and response to second-line chemotherapy. On multivariate analysis only normal baseline LDH retained statistical significance. Thirty-five patients went on to receive chemotherapy beyond the third line. CONCLUSION: Few SCLC patients receive 3 chemotherapy lines. Most patients were rechallenged with a similar regimen at least once. Response and survival in the third-line setting are modest. Lack of response to second-line chemotherapy and elevated baseline LDH level might predict lack of benefit from third-line treatment. This data set does not include patients receiving fewer lines for comparison.
INTRODUCTION:Small-cell lung cancer is an aggressive disease for which the mainstay of treatment is chemotherapy. Despite good initial responses most patients will relapse. Some will receive second-line therapy with clinical benefit, but for third-line chemotherapy there is little evidence to guide treatment decisions and the benefits of treatment are unknown. This study investigated the treatment of SCLC in the third-line setting. PATIENTS AND METHODS: An international, multicenter retrospective analysis of patients who received at least 3 lines of chemotherapy for their SCLC was performed. RESULTS: From 2000 to 2010, 120 patients were identified from 5 centers: median age 61, 40% (n = 72) limited stage, and 79% (n = 95) Eastern Cooperative Oncology Group performance status of 0 to 1. Only 22% of these patients received 3 distinct lines of chemotherapy. The remainder were rechallenged with a chemotherapy regimen used at least once previously. Six percent received platinum-based chemotherapy in all 3 lines. In third-line, response rate was 18% and median overall survival was 4.7 months. Factors associated with longer survival included normal baseline LDH levels and response to second-line chemotherapy. On multivariate analysis only normal baseline LDH retained statistical significance. Thirty-five patients went on to receive chemotherapy beyond the third line. CONCLUSION: Few SCLCpatients receive 3 chemotherapy lines. Most patients were rechallenged with a similar regimen at least once. Response and survival in the third-line setting are modest. Lack of response to second-line chemotherapy and elevated baseline LDH level might predict lack of benefit from third-line treatment. This data set does not include patients receiving fewer lines for comparison.
Authors: Barbara Melosky; Parneet K Cheema; Anthony Brade; Deanna McLeod; Geoffrey Liu; Paul Wheatley Price; Kevin Jao; Devin D Schellenberg; Rosalyn Juergens; Natasha Leighl; Quincy Chu Journal: Oncologist Date: 2020-09-23
Authors: Charles M Rudin; M Catherine Pietanza; Todd M Bauer; Neal Ready; Daniel Morgensztern; Bonnie S Glisson; Lauren A Byers; Melissa L Johnson; Howard A Burris; Francisco Robert; Tae H Han; Sheila Bheddah; Noah Theiss; Sky Watson; Deepan Mathur; Bharathi Vennapusa; Hany Zayed; Satwant Lally; Donald K Strickland; Ramaswamy Govindan; Scott J Dylla; Stanford L Peng; David R Spigel Journal: Lancet Oncol Date: 2016-12-05 Impact factor: 41.316
Authors: Daniel Morgensztern; Benjamin Besse; Laurent Greillier; Rafael Santana-Davila; Neal Ready; Christine L Hann; Bonnie S Glisson; Anna F Farago; Afshin Dowlati; Charles M Rudin; Sylvestre Le Moulec; Satwant Lally; Sreeni Yalamanchili; Jürgen Wolf; Ramaswamy Govindan; David P Carbone Journal: Clin Cancer Res Date: 2019-09-10 Impact factor: 12.531
Authors: Amy B Hall; Dave Newsome; Yuxin Wang; Diane M Boucher; Brenda Eustace; Yong Gu; Brian Hare; Mac A Johnson; Sean Milton; Cheryl E Murphy; Darin Takemoto; Crystal Tolman; Mark Wood; Peter Charlton; Jean-Damien Charrier; Brinley Furey; Julian Golec; Philip M Reaper; John R Pollard Journal: Oncotarget Date: 2014-07-30